Stock Market Movers



Xilinx is the worldwide leader of programmable logic solutions. (PRNewsFoto/Xilinx)
SAN JOSE, Calif., Nov. 21, 2017 /PRNewswire/ -- Xilinx, Inc. (NASDAQ: XLNX), the leader in scalable and comprehensive All Programmable Industrial IoT (IIoT) platforms from Edge to Cloud, will showcase the latest solutions for Factory Automation, Smart Grid and Robotics applications at SPS IPC Drives 2017. Highlights include advancements in Time-Sensitive Networking (TSN) for Industrie 4.0, Machine Learning, Cybersecurity, Functional Safety, and Motor Control on Xilinx's All Programmable SoC and MPSoC-based solutions. Visit Xilinx at SPC IPC Drives 2017, Stand #266 in Hall 6, November 28-30, at Nuremberg Messe.
Hormel Foods corporate logo (PRNewsFoto/Hormel Foods Corporation)
AUSTIN, Minn., Nov. 21, 2017 /PRNewswire/ -- Hormel Foods Corporation (NYSE: HRL) today announced that Glenn Leitch will lead the company's global supply chain as its executive vice president of supply chain. Leitch is currently group vice president, Hormel Foods and president, Jennie-O Turkey Store. The move is part of the company's plan to make its supply chain a strategic competitive advantage, while optimizing it to deliver sustainable long-term growth. Hormel Foods procurement, manufacturing, logistics, research and development, and quality management will report to Leitch. Notably, the company will align pork procurement and all plant operations for both Refrigerated Foods and Grocery Products into the newly created group. The company's supply chain includes more than 30 production facilities and co-packing partners, producing thousands of products sold worldwide.
Hormel Foods corporate logo (PRNewsFoto/Hormel Foods Corporation)
AUSTIN, Minn., Nov. 21, 2017 /PRNewswire/ -- Hormel Foods Corporation (NYSE: HRL) today announced that its Specialty Foods segment has been merged into its Grocery Products segment and will continue to be led by Luis Marconi, group vice president, Grocery Products. The primary focus of the segment is on delivering a strong branded portfolio of leading products to the evolving retail environment of food, drug, mass, club and E-commerce.
Ardelyx logo (PRNewsFoto/Ardelyx) (PRNewsFoto/Ardelyx)
FREMONT, Calif., Nov. 21, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having received feedback from the United States Food and Drug Administration (FDA) on the trial design. In addition, Ardelyx reported clinically meaningful potassium lowering activity from its onset-of-action study for RDX7675 for the treatment of hyperkalemia; however, the company also observed an unexpected side effect of decreased serum bicarbonate. The company believes this will limit the commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675. This change will result in a cash savings of approximately $40 million to Ardelyx over the next two years, extending the company's operating runway into 2019.